IL320576A - Oral formulation of a derivative of n-pyridinyl acetamide for the treatment of interstitial lung disease - Google Patents

Oral formulation of a derivative of n-pyridinyl acetamide for the treatment of interstitial lung disease

Info

Publication number
IL320576A
IL320576A IL320576A IL32057625A IL320576A IL 320576 A IL320576 A IL 320576A IL 320576 A IL320576 A IL 320576A IL 32057625 A IL32057625 A IL 32057625A IL 320576 A IL320576 A IL 320576A
Authority
IL
Israel
Prior art keywords
lung disease
oral formulation
interstitial lung
acetamide derivative
treating interstitial
Prior art date
Application number
IL320576A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL320576A publication Critical patent/IL320576A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL320576A 2022-11-04 2025-04-29 Oral formulation of a derivative of n-pyridinyl acetamide for the treatment of interstitial lung disease IL320576A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263382311P 2022-11-04 2022-11-04
PCT/EP2023/080652 WO2024094844A1 (en) 2022-11-04 2023-11-03 Oral formulation of n-pyridinyl acetamide derivative for treating interstitial lung disease

Publications (1)

Publication Number Publication Date
IL320576A true IL320576A (en) 2025-07-01

Family

ID=88689993

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320576A IL320576A (en) 2022-11-04 2025-04-29 Oral formulation of a derivative of n-pyridinyl acetamide for the treatment of interstitial lung disease

Country Status (14)

Country Link
JP (1) JP2025536575A (es)
KR (1) KR20250099240A (es)
CN (1) CN120187430A (es)
AR (1) AR130952A1 (es)
AU (1) AU2023374727A1 (es)
CL (1) CL2025001306A1 (es)
CO (1) CO2025007400A2 (es)
CR (1) CR20250229A (es)
DO (1) DOP2025000103A (es)
IL (1) IL320576A (es)
MX (1) MX2025005174A (es)
PE (1) PE20251575A1 (es)
TW (1) TW202434248A (es)
WO (1) WO2024094844A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017007218B1 (pt) 2014-10-08 2023-10-10 Redx Pharma Plc Derivados de n-piridil acetamida como inibidores da via de sinalização de wnt, formulações farmacêuticas compreendendo os mesmos e seus usos

Also Published As

Publication number Publication date
TW202434248A (zh) 2024-09-01
CR20250229A (es) 2025-07-11
DOP2025000103A (es) 2025-06-15
CL2025001306A1 (es) 2025-08-01
WO2024094844A1 (en) 2024-05-10
KR20250099240A (ko) 2025-07-01
PE20251575A1 (es) 2025-06-12
CN120187430A (zh) 2025-06-20
AR130952A1 (es) 2025-02-05
JP2025536575A (ja) 2025-11-07
CO2025007400A2 (es) 2025-06-16
MX2025005174A (es) 2025-06-02
AU2023374727A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
IL299167A (en) Compositions and methods for treating patients with gene therapy
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
AU2024216821A1 (en) Rifabutin analogs for the treatment of bacterial diseases
DK4426307T3 (da) Ny oral farmaceutisk sammensætning og doseringsplan til behandling af progressive fibroserende interstitielle lungesygdomme
CA3263467A1 (en) COMPOUNDS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS AND DISEASES
CA3266876A1 (en) RIFABUTINE ANALOGUES FOR THE TREATMENT OF A DISEASE
CA3272254A1 (en) Oral formulation of n-pyridinyl acetamide derivative for treating interstitial lung disease
AU2024317483A1 (en) Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
IL320242A (en) Compounds and their use for the treatment of hemoglobinopathy
GB202313514D0 (en) Treatment of inflammatory diseases
GB202202761D0 (en) Compositions for treatment of dental caries
DOP2025000103A (es) Formulación oral de derivado de n-piridinilacetamida para tratar la enfermedad pulmonar intersticial
EP4405469A4 (en) COMPOSITIONS USEFUL FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE
HK40121149A (en) Oral octreotide for treatment of disease
PL4106783T3 (pl) Kompozycja do leczenia chorób skóry i błon śluzowych
IL327399A (en) Compounds and medicinal preparations containing them for the treatment of diseases
GB202403324D0 (en) Compounds for the treatment of skin diseases
LT4648753T (lt) Kompozicijos, skirtos cftr nulemtų ligų gydymui
IL314586A (en) Compositions and methods for improved treatment of Pompe disease
GB202315831D0 (en) Treatment of skin disease
GB202404416D0 (en) Treatment of disease
HK40105820A (en) Methods and compositions for treatment of disease
EP4304624A4 (en) METHODS AND COMPOSITIONS FOR THE TREATING OF DISEASES
CA3297926A1 (en) Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
CA3278922A1 (en) Rifabutin analogs for the treatment of bacterial diseases